<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04020913</url>
  </required_header>
  <id_info>
    <org_study_id>#19-09</org_study_id>
    <secondary_id>U111112218502</secondary_id>
    <nct_id>NCT04020913</nct_id>
  </id_info>
  <brief_title>Skeletal Muscle Effects of GH in Boys</brief_title>
  <official_title>Recombinant Human Growth Hormone (GH): Effects on Metabolic Profile, Body Composition and Skeletal Muscle Strength and Function in Pre-pubertal Short Boys With and Without GH Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to measure the functional effects of recombinant GH in skeletal&#xD;
      muscle, in addition to growth promotion, in short prepubertal boys with either growth hormone&#xD;
      deficiency or idiopathic short stature. Patients will be similarly short. The investigators&#xD;
      will also compare these values in the short stature cohort to those obtained in testing&#xD;
      performed in normally growing age-matched healthy control boys not on GH. The group on GH&#xD;
      will be studied before and after 6 and 12 months of GH treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prepubertal boys with significant short stature (height SDS ≤-2.0) diagnosed with either GH&#xD;
      deficiency or idiopathic short stature (ISS) who are identified as candidates for GH&#xD;
      treatment will recruited. Subjects will have a battery of studies to assess skeletal muscle&#xD;
      strength, agility, power and endurance, as well as assessment of body composition and energy&#xD;
      expenditure before and after GH administration. GH (Somatropin) treatment at standard doses&#xD;
      will be given as daily injections at bedtime. Subjects will be followed at three-month&#xD;
      intervals per the clinical routine, when anthropometric measurements will be obtained.&#xD;
      Baseline studies will be repeated at 6 and 12 months from initiation of treatment, each&#xD;
      patient will serve as his own control pre and post GH.&#xD;
&#xD;
      A group of normally statured healthy boys will have the same testing as the study patients&#xD;
      but without GH treatment to assess the impact of natural growth on the muscle measures above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">July 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 21, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal muscle strength (Newtons)</measure>
    <time_frame>12 months</time_frame>
    <description>Upper and lower body muscle strength will be assessed using a handheld dynamometer for manual muscle testing of peak force</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle power (Watts)</measure>
    <time_frame>12 months</time_frame>
    <description>Lower extremity power will be assessed by vertical jump performed using a Power time mat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle agility (seconds)</measure>
    <time_frame>12 months</time_frame>
    <description>Muscle agility will be assessed by a timed shuttle run</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle endurance</measure>
    <time_frame>12 months</time_frame>
    <description>Upper body muscular endurance will be assessed using a modified push up test for repetitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass accrual</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by dual energy x-ray absorptiometry (DEXA) scan of the whole body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by DEXA scan of the lumbar spine and whole body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting energy expenditure</measure>
    <time_frame>12 months</time_frame>
    <description>Indirect calorimetry will be performed after overnight fast</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <condition>Idiopathic Short Stature</condition>
  <arm_group>
    <arm_group_label>Short Stature Boys</arm_group_label>
    <description>Prepubertal boys with short stature defined as a height ≤-2 SDS with either GH deficiency (defined as peak GH responses to pharmacologic stimuli &lt;10ng/ml) or idiopathic short stature (i.e., no identifiable pathology) will be studied pre and post 12 months of GH therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normally Statured Boys</arm_group_label>
    <description>A group of 15 healthy, normally statured (between 10th- 90th %), age-matched boys not on Growth Hormone replacement, preferably siblings (although not exclusively), will be recruited to serve as healthy controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin injection</intervention_name>
    <description>Boys with short stature will be studied for measures of:&#xD;
skeletal muscle strength, power, and endurance&#xD;
muscle agility&#xD;
lean body mass accrual&#xD;
bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration</description>
    <arm_group_label>Short Stature Boys</arm_group_label>
    <other_name>Recombinant Growth Hormone</other_name>
    <other_name>Norditropin</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum/plasma will be obtained.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prepubertal boys with short stature defined as a height ≤-2 SDS with either GH deficiency&#xD;
        (i.e., peak GH responses to pharmacologic stimuli &lt;10ng/ml) or idiopathic short stature&#xD;
        (i.e., normal GH, no identifiable pathology) will be studied.&#xD;
&#xD;
        Normally Statured Boys: A group of 15 healthy, normally statured (between 10th- 90th %),&#xD;
        age-matched boys not on somatropin, preferably siblings (although not exclusively) will be&#xD;
        studied similarly.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Short Stature Group&#xD;
&#xD;
          1. 30 boys between 6-11 years of age&#xD;
&#xD;
          2. Prepubertal&#xD;
&#xD;
          3. Short stature (height ≤ -2SDS) due to either GH deficiency or idiopathic&#xD;
&#xD;
          4. Stable treatment of other pituitary hormone deficiencies&#xD;
&#xD;
          5. Naïve to GH therapy, or GH discontinued at least 6 months prior to study&#xD;
&#xD;
        Normal Stature Group&#xD;
&#xD;
          1. 15 boys between 6-11 years of age&#xD;
&#xD;
          2. Prepubertal&#xD;
&#xD;
          3. Normal height (10th to 90th%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Actively growing brain tumors&#xD;
&#xD;
          2. Chronic medical conditions that could affect study outcomes&#xD;
&#xD;
          3. Long-term steroid use&#xD;
&#xD;
          4. Intense regular physical training programs or organized team sports&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelly Mauras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nelly Mauras, MD</last_name>
    <phone>904-697-3674</phone>
    <email>nmauras@nemours.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lurah Welch, MD</last_name>
    <phone>904-697-3815</phone>
    <email>Lurah.welch@nemours.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelly Mauras, MD</last_name>
      <phone>904-697-3674</phone>
      <email>nmauras@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Nelly Mauras, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GH</keyword>
  <keyword>muscle strength</keyword>
  <keyword>prepubertal</keyword>
  <keyword>boys</keyword>
  <keyword>short stature</keyword>
  <keyword>GH treatment</keyword>
  <keyword>muscle agility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

